Talaris Therapeutics

OverviewSuggest Edit

Talaris Therapeutics is a late-clinical stage biotechnology company that is developing cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The Company's proprietary technology allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs) safely from unmatched and unrelated donors, without the toxicity and risks of a traditional bone marrow transplant.

TypePrivate
Founded2002
HQLouisville, KY, US
Websitetalaristx.com

Latest Updates

Employees (est.) (Jan 2021)54(+2%)
Cybersecurity ratingAMore

Key People/Management at Talaris Therapeutics

Scott Requadt

Scott Requadt

Chief Executive Officer
Suzanne Ildstad

Suzanne Ildstad

Chief Scientific Officer and Founder
Nancy Krieger

Nancy Krieger

Chief Medical Officer
Keith McCormick

Keith McCormick

Vice President of Finance
Gregg Beloff

Gregg Beloff

Acting Chief Financial Officer
Michael Zdanowski

Michael Zdanowski

Chief Technology Officer
Show more

Talaris Therapeutics Office Locations

Talaris Therapeutics has offices in Louisville and Wellesley
Louisville, KY, US (HQ)
201 E Jefferson St #110BLouisville
Louisville, KY, US
570 S Preston St
Wellesley, MA, US
93 Worcester St #120
Show all (3)

Talaris Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2002

Talaris Therapeutics total Funding

$215 m

Talaris Therapeutics latest funding size

$115 m

Time since last funding

2 months ago

Talaris Therapeutics investors

Talaris Therapeutics's latest funding round in November 2020 was reported to be $115 m. In total, Talaris Therapeutics has raised $215 m
Show all financial metrics

Talaris Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Talaris Therapeutics Online and Social Media Presence

Embed Graph

Talaris Therapeutics Blogs

Talaris Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

BOSTON, Mass., and LOUISVILLE, Ky., January 8, 2021 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, is scheduled to virtually present at the 39th An…

Talaris Therapeutics Expands Leadership Team with Appointments of Accomplished Executives in Manufacturing, Portfolio Strategy and Clinical Operations

BOSTON, Mass., and LOUISVILLE, Ky., November 12, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the expansion of its senior le…

Talaris Therapeutics lands $115M in venture capital funding

Louisville Business First: The is the second time in about 18 months that this company has turned heads with its capital raises. FULL STORY The post Talaris Therapeutics lands $115M in venture capital funding appeared first on Talaris.

Talaris Therapeutics Closes $115 Million Series B Financing

Proceeds to support ongoing Phase 3 registration trial of Talaris’ lead product candidate FCR001 in living donor kidney transplant, and additional Phase 2 trials next year in autoimmune disease and organ transplant Financing co-led by Surveyor Capital (a Citadel company) and Viking Global Investors,…

Talaris awarded 2020 Citeline Award for Clinical Trial Result of the Year

On September 17, 2020, Talaris was awarded the 2020 Citeline Award for Clinical Trial Result of the Year.  This award recognizes the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare. The judges sought to recognize the clinical tri…

Health Care Heroes 2020

Members of the Louisville business community gathered Tuesday night to recognize and celebrate 31 health care professionals at Louisville Business First’s 2020 Health Care Heroes banquet. Scott Requadt, CEO of Talaris Therapeutics Inc., headlined the event with a keynote address and question-and-ans…
Show more

Talaris Therapeutics Frequently Asked Questions

  • When was Talaris Therapeutics founded?

    Talaris Therapeutics was founded in 2002.

  • Who are Talaris Therapeutics key executives?

    Talaris Therapeutics's key executives are Scott Requadt, Suzanne Ildstad and Nancy Krieger.

  • How many employees does Talaris Therapeutics have?

    Talaris Therapeutics has 54 employees.

  • Who are Talaris Therapeutics competitors?

    Competitors of Talaris Therapeutics include ALX Oncology, Storm Therapeutics and Actym Therapeutics.

  • Where is Talaris Therapeutics headquarters?

    Talaris Therapeutics headquarters is located at 201 E Jefferson St #110BLouisville, Louisville.

  • Where are Talaris Therapeutics offices?

    Talaris Therapeutics has offices in Louisville and Wellesley.

  • How many offices does Talaris Therapeutics have?

    Talaris Therapeutics has 3 offices.